rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    RNAZ
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      TransCode Therapeutics explores strategic alternatives
      Oct 28Investing.comRNAZ
      TransCode Therapeutics Presents Phase 1a Clinical Data for TTX-MC138 at ESMO Congress 2026

      --TransCode Therapeutics, Inc., a clinical-stage company pioneering immuno-oncology and RNA-based therapeutics for the treatment of high-risk and advanced cancers, released its poster 1025 P describing the clinical results from its Phase 1 a clinical trial of TTX-MC138 at the European Society for Medical Oncology Congress 2026 in Madrid, Spain.

      Oct 26NasdaqRNAZ
      Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer
      Oct 13Yahoo FinanceNTRARNAZ
      TransCode Therapeutics Eases Near-Term Obligations Under Financing

      Detailed price information for Transcode Therapeutics Inc (RNAZ-Q) from The Globe and Mail including charting and trades.

      Oct 2The Globe and MailRNAZ
      TransCode Therapeutics makes $840,975 prepayment under convertible notes agreement
      Oct 1Investing.comRNAZ
      TransCode Reports Continued Disease Stabilization and Extended Treatment Duration with TTX-MC138 in Ongoing Phase 1a Clinical Trial Follow-Up

      --TransCode Therapeutics, Inc., a clinical stage company pioneering immuno-oncology and RNA-based therapeutics for the treatment of high risk and advanced cancers, today announced updated clinical data from its Phase 1 a clinical trial of TTX-MC138, its novel anti-miR-10b therapeutic candidate, in patients with relapsed or refractory, unresectable...

      Sep 28NasdaqRNAZ
      TransCode receives patent approvals in Australia and Japan
      Sep 22Investing.comRNAZ
      Join Today's Live Investor Webinar with TransCode Therapeutics

      Learn how TransCode Therapeutics is advancing RNA therapeutics, cancer vaccines, and immuno-oncology programs designed to address advanced and metastatic cancersManagement to discuss TTX-MC138, the ongoing Phase 2a colorectal cancer trial, tumor-targeted RNA delivery, and multiple upcoming clinical catalystsORLANDO, FL / ACCESS Newswire / September 16, 2026 / RedChip Companies will host an investor webinar today, September 16, 2026, at 4:15 p. ET with TransCode Therapeutics, Inc.

      Sep 16Yahoo FinanceRNAZ
      Transcode Therapeutics announces CFO resignation and interim appointment
      Sep 11Investing.comRNAZ
      TransCode Therapeutics Announces Leadership Transition
      Sep 10Yahoo FinanceRNAZ
      Join TransCode Therapeutics' Live Investor Webinar: Advancing a Multi-Platform Oncology Pipeline Targeting Metastatic Cancer

      Learn how TransCode Therapeutics is advancing RNA therapeutics, cancer vaccines, and immuno-oncology programs designed to address advanced and metastatic cancersManagement to discuss TTX-MC138, the ongoing Phase 2a colorectal cancer trial, tumor-targeted RNA delivery, and multiple upcoming clinical catalystsORLANDO, FL / ACCESS Newswire / September 3, 2026 / RedChip Companies will host an investor webinar on Wednesday, September 16, 2026, at 4:15 p. ET with TransCode Therapeutics, Inc.

      Sep 3Yahoo FinanceRNAZ

      This is the newest page. Registered accounts read further back.